

CAMP Conference- Overall Learning Objectives:

1. Review the increasingly complex landscape of molecular testing across major cancer types.
2. Prepare pathologists with knowledge for incorporating molecular reporting into anatomical pathology reports.
3. Recognize the importance of molecular pathology in cancer screening.
4. Explore new avenues to harmonize tissue testing and liquid biopsy.
5. Recognize and strengthen collaborative efforts within the cancer care team.

Friday, April 12, 2024
Fairmont Chateau Whistler – Empress Ballroom

5:00 pm – 7:00 pm

Registration

Saturday, April 13, 2024
Twenty-five Percent (25%) of program time has been allotted for Interactive Learning

6:30 am

Registration

6:30 am – 7:00 am

Breakfast – Empress Ballroom

7:00 am – 7:15 am

Welcoming Remarks – Dr. Diana Ionescu (Vancouver, BC)

7:15 am – 8:00 am

 Cervical Cancer Screening – A Global Overview with a BC Focus
– Dr. Gina Ogilvie (British Columbia, Canada)

As a result of attending this session the attendees will be able to::

1. Understand the evidence base for the transition from Pap smears to HPV based screening
2. Describe the experience with a pilot provincial at-home cervix screening program

8:00 am – 8:15 am

Question and Answer

8:15 am – 9:00 am

 Molecular Pathology of Ovarian Cancer – The Central Role of
Pathologist – Dr. Frederique Penault-Llorca (France)

As a result of attending this session the attendees will be able to:

	<ol style="list-style-type: none"> 1. Understanding the biology of high grade serous ovarian carcinoma and the implication for Parpi 2. Understanding the development of molecular tests for HDR testing 3. Understanding the role of molecular diagnosis for the characterization of rare ovarian tumors
9:00 am – 9:15 am	Question and Answer
9:15 am – 9:45 am	Refreshment Break and Visit with the Sponsors
9:45 am – 10:30 am	<p>Molecular Pathology of Gastrointestinal Cancers – Dr. David Schaeffer (British Columbia, Canada)</p> <p>As a result of attending this session the attendees will be able to:</p> <ol style="list-style-type: none"> 1. Review classification and molecular subtyping of gastric adenocarcinoma. 2. Discuss clinically relevant scenarios requiring pathologist judgement for application of molecular tests in GI pathology entities. 3. Integrate interpretive comments for select GI pathology diagnoses.
10:30 am – 10:45 am	Question and Answers
10:45 am – 11:30 am	<p>Pathologists Supporting Clinical Trials – Integration of Biomarker Use in Endometrial Cancer – Dr. Mary Kinloch (Saskatchewan, Canada)</p> <p>As a result of attending this session the attendees will be able to:</p> <ol style="list-style-type: none"> 1. Demonstrate the companion biomarker interpretation of endometrial cancer (MMR, p53, ER, POLE). 2. Review the common interpretive pitfalls of biomarkers for molecular endometrial adenocarcinoma. 3. Integrate biomarkers into a theranostic pathology report (and how to handle when the IHC and NGS do not match). 4. Review the current clinical trials (EN.10 and EN.11) and how treatment is changing based on biomarker reporting.
11:30 am – 11:45 am	Question and Answer
11:45 am – 1:00 pm	Lunch

1:15 pm – 2:00 pm	<p>Thyroid Molecular Pathology – Dr. Vania Nosé (Massachusetts, USA)</p> <p>As a result of attending this session the attendees will be able to:</p> <ol style="list-style-type: none"> 1. Be aware with the newly implemented WHO terminology of thyroid lesions associated with gene alterations 2. Understand familial syndromes involving thyroid: from genetic cancer susceptibility to newly established endocrine syndromes 3. Be acquainted with the classical thyroid findings in PTEN-hamartoma tumor syndrome/Cowden disease 4. Understand the diverse pathological findings of DICER1-related thyroid tumors
2:00 pm – 2:15 pm	Question and Answer
2:15 pm – 2:30 pm	Refreshment Break and Visit with the Sponsors
2:30 pm – 3:15 pm	<p>The Landscape of Biomarkers in Breast Cancer – Dr. Zuzana Kos (British Columbia, Canada)</p> <p>As a result of attending this session the attendees will be able to:</p> <ol style="list-style-type: none"> 1. Describe the biomarker tests and their role in the management of early-stage versus metastatic breast cancer. 2. Compare and contrast the various assays available for biomarker testing in breast cancer. 3. Illustrate the role of multidisciplinary care and the role of the pathologist in breast cancer.
3:15 pm – 3:30 pm	Question and Answers
3:30 pm – 4:15 pm	<p>Search and Research: From Histological Observation to Scientific Discovery – Dr. Gao Zu-Hua (British Columbia, Canada)</p> <p>As a result of attending this session the attendees will be able to:</p> <ol style="list-style-type: none"> 1. Share personal experiences in conducting clinically relevant research inspired by histological observation under the microscope on the following projects: <ul style="list-style-type: none"> • Hepatocellular carcinoma • Colorectal carcinoma • Pancreatic ductal adenocarcinoma • Liquid biopsy
4:15 pm – 4:30 pm	Question and Answer

4:30 pm	Closing Remarks for the Day – Dr. Diana Ionescu
6:00 pm – 8:00 pm	Welcome Reception and Visit with the Sponsors
Sunday, April 14, 2024	
Empress Ballroom	
Twenty-five Percent (25%) of program time has been allotted for Interactive Learning	
6:30 am – 7:30 am	Breakfast
7:30 am	Introduction – Dr. Diana Ionescu
7:30 am – 8:30 am	<p>Liquid Biopsy in the Cancer Care Continuum from Screening to Acquired Resistance – Dr. David Gandara (California, USA)</p> <p>As a result of attending this session the attendees will be able to:</p> <ol style="list-style-type: none"> 1. Define the scope of liquid biopsy in cancer from source (plasma or other) to methodology (NGS or other) to components (genomics, methylation, other) 2. Understand how liquid biopsy fits into precision medicine approaches to cancer diagnosis and care. 3. Give examples of liquid biopsy transitioning from research to standard of care
8:30 am – 9:15 am	<p>Challenges and Opportunities in Liquid Biopsy Implementation: Perspective from the Canadian Perspective – Dr. Patrice Desmeules (Quebec, Canada)</p> <p>As a result of attending this session the attendees will be able to:</p> <ol style="list-style-type: none"> 1. Describe the main challenges in liquid biopsy assay implementation 2. Understand the trajectory of complex assay development in a public health system 3. Identify key indicators deemed to support regulatory approval of non-invasive molecular testing
9:15 am – 9:45 am	Addressing Testing Challenges in Molecular Pathology: Fireside Chat (Multiple Panelists)
9:45 am – 10:00 am	Refreshment Break

10:00 am – 12:00 pm	From Germline to Somatic: Clinical Application of Molecular Pathology Real-World Cases
	Discussion Includes a Multidisciplinary Panel
	Case Presenters on Panel:
	Pathologist 1: Dr. Frederique Penault-Llorca
	Pathologist 2: Dr. Vania Nosé
	Pathologist 3: Dr. David Gandara
	Medical Oncologist 4: Dr. Cheryl Ho
12:00 pm – 12:05 pm	Closing Remarks – Dr. Diana Ionescu